Another recombinant IgG-like bispecific antibody (FL-BsAb1/17) targeting IL-1β and IL-17A also showed considerable effects for RA treatment, which could repress the secretion of IL-6 in FLS from patients with RA (73). This evidence concerns the gene IL6 and rheumatoid arthritis.